Matches in SemOpenAlex for { <https://semopenalex.org/work/W2196133620> ?p ?o ?g. }
- W2196133620 endingPage "2421" @default.
- W2196133620 startingPage "2413" @default.
- W2196133620 abstract "Background Polio eradication needs a new routine immunisation schedule—three or four doses of bivalent type 1 and type 3 oral poliovirus vaccine (bOPV) and one dose of inactivated poliovirus vaccine (IPV), but no immunogenicity data are available for this schedule. We aimed to assess immunogenicity of this vaccine schedule. Methods We did an open-label, randomised controlled trial in four centres in India. After informed consent was obtained from a parent or legally acceptable representative, healthy newborn babies were randomly allocated to one of five groups: trivalent OPV (tOPV); tOPV plus IPV; bOPV; bOPV plus IPV; or bOPV plus two doses of IPV (2IPV). The key eligibility criteria were: full-term birth (≥37 weeks of gestation); birthweight ≥2·5 kg; and Apgar score of 9 or more. OPV was administered at birth, 6 weeks, 10 weeks, and 14 weeks; IPV was administered intramuscularly at 14 weeks. The primary study objective was to investigate immunogenicity of the new vaccine schedule, assessed by seroconversion against poliovirus types 1, 2, and 3 between birth and 18 weeks in the per-protocol population (all participants with valid serology results on cord blood and at 18 weeks). Neutralisation assays tested cord blood and sera collected at 14 weeks, 18 weeks, 19 weeks, and 22 weeks by investigators masked to group allocation. This trial was registered with the India Clinical Trials Registry, number CTRI/2013/06/003722. Findings Of 900 newborn babies enrolled between June 13 and Aug 29, 2013, 782 (87%) completed the per-protocol requirements. Between birth and age 18 weeks, seroconversion against poliovirus type 1 in the tOPV group occurred in 162 of 163 (99·4%, 95% CI 96·6–100), in 150 (98·0%, 94·4–99·6) of 153 in the tOPV plus IPV group, in 153 (98·7%, 95·4–99·8) of 155 in the bOPV group, in 155 (99·4%, 96·5–100) of 156 in the bOPV plus IPV group, and in 154 (99·4%, 96·5–100) of 155 in the bOPV plus 2IPV group. Seroconversion against poliovirus type 2 occurred in 157 (96·3%, 92·2–98·6) of 163 in the tOPV group, 153 (100%, 97·6–100·0) of 153 in the tOPV plus IPV group, 29 (18·7%, 12·9–25·7) of 155 in the bOPV group, 107 (68·6%, 60·7–75·8) of 156 in the bOPV plus IPV group, and in 121 (78·1%, 70·7–84·3) of 155 in the bOPV plus 2IPV group. Seroconversion against poliovirus type 3 was achieved in 147 (90·2%, 84·5–94·3) of 163 in the tOPV group, 152 (99·3%, 96·4–100) of 153 in the tOPV plus IPV group, 151 (97·4%, 93·5–99·3) of 155 in the bOPV group, 155 (99·4%, 96·5–100) of 156 in the bOPV plus IPV group, and 153 (98·7%, 95·4–99·8) of 155 in the bOPV plus 2IPV group. Superiority was achieved for vaccine regimens including IPV against poliovirus type 3 compared with those not including IPV (tOPV plus IPV vs tOPV alone, p=0·0008; and bOPV plus IPV vs bOPV alone, p=0·0153). 12 serious adverse events occurred (six in the tOPV group, one in the tOPV plus IPV group, three in the bOPV group, zero in the bOPV plus IPV group, and two in the bOPV plus 2IPV group), none of which was attributed to the trial intervention. Interpretation The new vaccination schedule improves immunogenicity against polioviruses, especially against poliovirus type 3. Funding WHO, through a grant from Rotary International (grant number 59735)." @default.
- W2196133620 created "2016-06-24" @default.
- W2196133620 creator A5010163820 @default.
- W2196133620 creator A5018534101 @default.
- W2196133620 creator A5036590679 @default.
- W2196133620 creator A5037477467 @default.
- W2196133620 creator A5042324494 @default.
- W2196133620 creator A5044715375 @default.
- W2196133620 creator A5046058004 @default.
- W2196133620 creator A5050192915 @default.
- W2196133620 creator A5050656770 @default.
- W2196133620 creator A5060936375 @default.
- W2196133620 creator A5070209591 @default.
- W2196133620 creator A5070369489 @default.
- W2196133620 creator A5071125656 @default.
- W2196133620 creator A5074709905 @default.
- W2196133620 creator A5076319279 @default.
- W2196133620 creator A5081854515 @default.
- W2196133620 creator A5087307729 @default.
- W2196133620 date "2015-12-01" @default.
- W2196133620 modified "2023-10-18" @default.
- W2196133620 title "Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial" @default.
- W2196133620 cites W2020809345 @default.
- W2196133620 cites W2045970981 @default.
- W2196133620 cites W2072881891 @default.
- W2196133620 cites W2081176035 @default.
- W2196133620 cites W2082184261 @default.
- W2196133620 cites W2087515282 @default.
- W2196133620 cites W2097965467 @default.
- W2196133620 cites W2098993743 @default.
- W2196133620 cites W2100566497 @default.
- W2196133620 cites W2103683759 @default.
- W2196133620 cites W2106168554 @default.
- W2196133620 cites W2107376649 @default.
- W2196133620 cites W2137591261 @default.
- W2196133620 cites W2152731419 @default.
- W2196133620 cites W2171567692 @default.
- W2196133620 cites W2217538693 @default.
- W2196133620 cites W2335890187 @default.
- W2196133620 cites W4384466965 @default.
- W2196133620 doi "https://doi.org/10.1016/s0140-6736(15)00237-8" @default.
- W2196133620 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26388534" @default.
- W2196133620 hasPublicationYear "2015" @default.
- W2196133620 type Work @default.
- W2196133620 sameAs 2196133620 @default.
- W2196133620 citedByCount "53" @default.
- W2196133620 countsByYear W21961336202014 @default.
- W2196133620 countsByYear W21961336202015 @default.
- W2196133620 countsByYear W21961336202016 @default.
- W2196133620 countsByYear W21961336202017 @default.
- W2196133620 countsByYear W21961336202018 @default.
- W2196133620 countsByYear W21961336202019 @default.
- W2196133620 countsByYear W21961336202020 @default.
- W2196133620 countsByYear W21961336202021 @default.
- W2196133620 countsByYear W21961336202022 @default.
- W2196133620 countsByYear W21961336202023 @default.
- W2196133620 crossrefType "journal-article" @default.
- W2196133620 hasAuthorship W2196133620A5010163820 @default.
- W2196133620 hasAuthorship W2196133620A5018534101 @default.
- W2196133620 hasAuthorship W2196133620A5036590679 @default.
- W2196133620 hasAuthorship W2196133620A5037477467 @default.
- W2196133620 hasAuthorship W2196133620A5042324494 @default.
- W2196133620 hasAuthorship W2196133620A5044715375 @default.
- W2196133620 hasAuthorship W2196133620A5046058004 @default.
- W2196133620 hasAuthorship W2196133620A5050192915 @default.
- W2196133620 hasAuthorship W2196133620A5050656770 @default.
- W2196133620 hasAuthorship W2196133620A5060936375 @default.
- W2196133620 hasAuthorship W2196133620A5070209591 @default.
- W2196133620 hasAuthorship W2196133620A5070369489 @default.
- W2196133620 hasAuthorship W2196133620A5071125656 @default.
- W2196133620 hasAuthorship W2196133620A5074709905 @default.
- W2196133620 hasAuthorship W2196133620A5076319279 @default.
- W2196133620 hasAuthorship W2196133620A5081854515 @default.
- W2196133620 hasAuthorship W2196133620A5087307729 @default.
- W2196133620 hasConcept C126322002 @default.
- W2196133620 hasConcept C159654299 @default.
- W2196133620 hasConcept C187212893 @default.
- W2196133620 hasConcept C203014093 @default.
- W2196133620 hasConcept C22070199 @default.
- W2196133620 hasConcept C2522874641 @default.
- W2196133620 hasConcept C2777451964 @default.
- W2196133620 hasConcept C2779631682 @default.
- W2196133620 hasConcept C2780868878 @default.
- W2196133620 hasConcept C2908647359 @default.
- W2196133620 hasConcept C4870876 @default.
- W2196133620 hasConcept C535046627 @default.
- W2196133620 hasConcept C71924100 @default.
- W2196133620 hasConcept C99454951 @default.
- W2196133620 hasConceptScore W2196133620C126322002 @default.
- W2196133620 hasConceptScore W2196133620C159654299 @default.
- W2196133620 hasConceptScore W2196133620C187212893 @default.
- W2196133620 hasConceptScore W2196133620C203014093 @default.
- W2196133620 hasConceptScore W2196133620C22070199 @default.
- W2196133620 hasConceptScore W2196133620C2522874641 @default.
- W2196133620 hasConceptScore W2196133620C2777451964 @default.
- W2196133620 hasConceptScore W2196133620C2779631682 @default.
- W2196133620 hasConceptScore W2196133620C2780868878 @default.
- W2196133620 hasConceptScore W2196133620C2908647359 @default.